Alicia Morgans, MD, MPH, Discusses How a Hypothetical Trial Cohort Demonstrates Impacts of Cabazitaxel Costs/Complications in mCRPC

Video

CancerNetwork® sat down with Alicia Morgans MD, MPH, at the 2021 European Society for Medical Oncology to discuss how a hypothetical cohort from the CARD trial highlighted the impact of treatment with cabazitaxel on costs and complications in patients with metastatic castration-resistant prostate cancer.

At the 2021 European Society of Medical Oncology Congress, CancerNetwork® spoke with Alicia Morgans, MD, MPH, director of Survivorship Program at Dana-Farber Cancer Institute, about a hypothetical cohort included in the phase 4 CARD trial (NCT02485691).

In addition to highlighting how findings from the cohort shed light on the impact of cabazitaxel (Jevtana) on the costs and complications that patients with metastatic castration-resistant prostate cancer may experience, as well as utilizing this information to better help patients.

Transcript:

We did observe that patients who were treated with cabazitaxel had fewer skeletal-related events, which was very important. The CARD study showed the differences in safety, and in this hypothetical cohort, what we did was apply the differences that already existed within that phase 4 trial to a population of patients. [This was] not to look for new differences, but to understand how that would impact patients in terms of hospital days, ICU days, and cost of care. We weren’t redefining rates of complication, but really taking the known rates from the trial and putting them into context in this setting.

Reference

Morgans AK, Hutson TE, Guan AK, et al. Clinical and cost impact of cabazitaxel versus (vs) a second androgen receptor targeted agent (ARTA) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and the alternative ARTA (abiraterone or enzalutamide). Presented at: 2021 European Society of Medical Oncology Congress; September 16-21, 2021; Virtual. Abstract 587P.

Recent Videos
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practice in the breast cancer field.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
4 experts in this video
4 experts in this video
Clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
Related Content